SARS-CoV-2 Lambda variant
Variant of SARS-CoV-2
The SARS-CoV-2 Lambda variant, also known as lineage C.37, is a variant of the virus SARS-CoV-2, which causes the disease COVID-19. This variant was first identified in Peru in August 2020 and has since spread to multiple countries. It is one of several variants of concern or interest that have emerged during the COVID-19 pandemic.
Genomic Characteristics[edit | edit source]
The Lambda variant is characterized by several mutations in the spike protein of the virus, which may affect its transmissibility and immune escape potential. Key mutations include L452Q and F490S, which are located in the receptor-binding domain of the spike protein. These mutations are thought to enhance the virus's ability to bind to the ACE2 receptor on human cells, potentially increasing its infectivity.
Epidemiology[edit | edit source]
The Lambda variant was first detected in Peru and quickly became the dominant strain in the country. It has also been reported in other South American countries, including Chile, Argentina, and Ecuador. The variant has been classified as a "variant of interest" by the World Health Organization due to its rapid spread and potential impact on public health.
Impact on Public Health[edit | edit source]
The Lambda variant's mutations may confer some degree of resistance to neutralizing antibodies generated by previous infection or vaccination. However, studies are ongoing to determine the exact impact of these mutations on vaccine efficacy. Public health authorities continue to monitor the spread of the Lambda variant and its effects on the course of the pandemic.
Prevention and Control[edit | edit source]
Efforts to control the spread of the Lambda variant include continued vaccination campaigns, genomic surveillance, and public health measures such as mask-wearing and social distancing. Vaccines currently in use have shown effectiveness against severe disease and hospitalization caused by various SARS-CoV-2 variants, including Lambda.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
